Key advances on immunotherapy and cellular therapy against cancer and inflammatory diseases

EUROBIOMED presents: key advances and future promises in immunotherapy antibodies and cellular therapies for the treatment of cancers and inflammatory diseases.

Over the last years, immunotherapies have shown very good results notably with the last generation of treatments combining different approaches for the treatment of melanoma and NSCLC. But despite the success and hope, these treatments generate severe adverse reactions, a high proportion of people still do not respond to immunotherapy, and their use in some pathologies are still in the preclinical phase. Lots of efforts are made in order to increase efficacy with new targets, new formats, combination of treatments and with the development of cellular therapies targeting the immune system. All these aspects will be addressed during this one day symposium and we will benefit from the point of view of the French pharmaceutical industry.



Registration and Coffee


Welcome words and Eurobiomed presentation

- Xavier Tabary, Sanofi

- Emilie Royere, Pôle Eurobiomed


The next generation of immunotherapy to increase efficacy (Part I)

- Dr Jean-Jacques Fournié (CRCT - Toulouse)

- Prof. Dr René Hoet (Imcheck Therapeutics - Marseille)

- Dr Julien Faget (IRCM - MabImprove - Montpellier)


Coffee Break


The next generation of immunotherapy to increase efficacy (Part II)

- Dr Nicolas Poirier (Ose Immunotherapeutics - Nantes)

- Dr Bruno Ségui (CRCT - Toulouse)

- Dr Hatem A. Azim (Innate Pharma - Marseille)

- Ms. Agnes Menut (MiMabs - Marseille)

12h20Lunch and networking

Afternoon Lecture

- Prof Christian Chabannon (CTCG, IPC - AP-HM - Marseille)

New cellular and genetic approaches to treat diseases (Part I)

- Dr Martin Villalba (IRMB - Montpellier)

- Dr Christine Duthoit (Flash Therapeutics - Toulouse)

15h00Coffee Break

New cellular and genetic approaches to treat diseases (Part II)

- Dr Caroline Courme (Sangamo - Nice)

16h00The pharmaceutical industry's point of view

- Dr. Leda MANNENT (Sanofi)

16h30Conference closing

Chairmen: Prof John De Vos (IRMB - Montpellier) and Prof Pierre Martineau (IRCM - Montpellier)


Registrations are now closed.


Information: Nicolas REYMOND: nicolas.reymond(at)eurobiomed(dot)org


With the support of



In partnership with